Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome
Status:
Withdrawn
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to obtain data or information on the safety and effectiveness
of low dose naltrexone (LDN) for treating the symptoms of juvenile primary fibromyalgia
syndrome. This is a dose finding study to find whether LDN helps the symptoms of juvenile
fibromyalgia, and at what dose it does so.